Panama7/iStock Editorial via Getty Images France-based healthcare company Sanofi ( NASDAQ: SNY ) is partnering with Formation Bio and Microsoft ( MSFT ) backed OpenAI to build AI-powered software to accelerate drug development, the companies said on Tuesday. The three companies will bring together data, software and tuned models to develop custom, purpose-built solutions across the drug development lifecycle. "This unique collaboration is the next significant step in our journey to becoming a pharmaceutical company substantially powered by AI," Sanofi CEO Paul Hudson said.
This partnership was led by OpenAI’s COO and approved by its independent Board of Directors. "There is massive potential for AI to accelerate drug development," OpenAI COO Brad Lightcap said. More on Sanofi Sanofi Q1: Wait And See For Now (Downgrade) Sanofi: Q1 Earnings Reflect Growth And Strategic Acquisitions (Rating Upgrade) Sanofi 2024 Q1 - Results - Earnings Call Presentation Sanofi gains license for ex-U.
S. rights to Fulcrum muscular dystrophy candidate Biggest stock movers today: ARM, ZK, TME, GME, and more.
